Ting-I LeeDr. Taiwan

• Endocrine Disrupting Chemicals Exposure and Human Health Outcomes in Different Populations
  Ching Chang LeeTaiwan Speaker Endocrine Disrupting Chemicals Exposure and Human Health Outcomes in Different PopulationsUp to now, public concerns about the impact of EDCs on human health is growing steadily. Phthalates are thyroid, reproductive and developmental toxicants. Maternal hypothyroidism during pregnancy can cause adverse effects in the fetus. Study 1 investigates the association between phthalate exposure and thyroid hormones in pregnant women. After adjusting for age, BMI and gestation, urinary MBP levels showed negative associations with FT4 and T4 (FT4:  = -0.110, P < 0.001; T4:  = -0.112, P = 0.003). Exposure to di-n-butyl phthalate (DBP) may affect thyroid activity in pregnant women. Study 2 evaluates the association between maternal urine excretion, the exposure of fetus to phthalates in amniotic fluid, and the health of newborns. We found a significant positive correlation between creatinine adjusted urinary MBP and amniotic fluid MBP (R2=0.156, P <0.05) in all infants and, only in female infants, a significantly negative correlation between amniotic fluid MBP, AGD (R = −0.31, P <0.06), and the anogenital index adjusted by birth weight (AGI-W) (R = −0.32, P <0.05). Our data clearly show that in utero exposure to phthalates in general has anti-androgenic effects on the fetus. Study 3 investigates the association between exposure to phthalates and female puberty, and assesses the effect of leuprorelin acetate treatment on kisspeptin-54 secretion in girls with CPP. All seven urinary phthalate metabolites in the CPP group were significantly higher than in prepubescent controls. Serum kisspeptin-54 level were higher (P = 0.022) in the CPP group than control group and still significantly higher after adjusting for age (P = 0.03). There was a significant increasing trend (Ptrend = 0.005) between levels of kisspeptin and the stages of puberty. Significantly positive correlation between kisspeptin-54 and urinary MBP (R2 = 0.109, P = 0.024) was found. Study 4 explores the biomarkers of altered testicular function associated with exposure to phthalates: the testosterone and INSL3 secretion of adult men with different fertility states. In multiple regression models controlled for potential confounders, there is an inverse association between urinary levels of MMP), mono-iso-butyl phthalate (MiBP), MEHP, MEHP% and serum TT (P = 0.001, 0.007, 0.042 and 0.012). The inverse associations were also found between urinary levels of MiBP, MBzP, MEHP, MEHP% and serum fT (P = 0.028, 0.017, 0.045 and 0.027). Urinary MBzP and MEHP% were negatively associated with a decrease in serum INSL3 (P = 0.049 and 0.001). We also observed a strong inverse relationship between MEHP% quartiles and serum TT, fT, the TT : LH ratio and INSL3 (Ptrend = 0.003, 0.080, 0.002 and 0.012). Serum INSL3, TT, fT and the TT : LH ratio were lower for men in the highest MEHP% quartile than in the reference group (P = 0.007, 0.002, 0.090 and 0.001). In conclusion, the present study showed that infertile men had poor Leydig cell functionality, higher levels of urinary phthalate metabolites and lower concentrations of androgens or INSL3, or both, which implied that being exposed to phthalates might affect human testicular steroidogenesis by impairing the function of Leydig cells. Study 5 investigated the active mechanisms of how being exposed to phthalates affects the imbalance of androgen and estrogen and the generation of ROS to determine whether both mediated phthalate-induced effects are involved in prostatic enlargement. DEHP metabolite levels, particularly urinary MEHP, were positively associated with androgen, estrogen, hormone ratios, inducible nitric oxide synthetase (iNOS), 8-OHdG, prostate specific antigen (PSA), and prostate volume (PV) (P < 0.05). PV and PSA were positively associated with androgen, estrogen, hormone ratios and oxidative stress markers (P < 0.05). The estimated percentages of exposure to phthalates in prostatic enlargement mediated by androgen, estrogen, and OS markers ranged from 3.5% to 63.1%. Exposure to DEHP promoted the progress of BPH by increasing dihydrotestosterone (DHT), estradiol (E2), the converted enzymes aromatase and 5 reductase, and reactive oxygen species (8-OHdG and iNOS) production. Sex hormones and OS might be important hyperplasia-promoters after a patient has been exposed to phthalates, especially to DEHP.
• Environmental Endocrinology: Interactions Between Environment and Hormonal Systems
  Vina Yanti SusantiIndonesia Speaker Environmental Endocrinology: Interactions Between Environment and Hormonal SystemsEnvironmental Endocrinology: Interactions Between Environment and Hormonal System Vina Yanti Susanti1 1 Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Gadjah Mada University, Dr. Sardjito Hospital, Yogyakarta, Indonesia Abstract The endocrine system serves as a sophisticated regulatory network essential for maintaining homeostasis, growth, and reproductive health through precise hormonal signaling. However, increasing exposure to environmental stressors—specifically Endocrine Disrupting Chemicals (EDCs)—has been shown to interfere with these pathways, posing significant risks to human health. This review explores the complex interactions between environmental pollutants and the hormonal system by dissecting the ten key functional characteristics of EDCs. The analysis categorizes these interactions into direct and indirect mechanisms. We examine how EDCs act as receptor agonists or antagonists, blocking natural hormones, and how they modulate receptor expression and signal transduction pathways. Furthermore, the review highlights the molecular impact of EDCs on epigenetic alterations, such as DNA methylation and histone modification. At the systemic level, we discuss the disruption of hormone synthesis, transport, distribution, and clearance. Finally, the review addresses the downstream consequences on cellular fate, including dysregulated proliferation, differentiation, and apoptosis. By integrating these ten dimensions, this paper emphasizes that environmental endocrine disruption is a multifaceted process rather than a single-point failure. Elucidating these integrated mechanisms provides a profound understanding of how environmental factors interact with and fundamentally reshape the body's internal hormonal landscape. Keywords: Environmental Endocrinology, Endocrine-Disrupting Chemicals (EDCs), Key Characteristic of Endocrine Disrupting Chemicals
• Emerging Endocrine Disrupting Chemicals and Their Impacts in Patients with Renal Disease
  Kai-Fan TsaiTaiwan Speaker Emerging Endocrine Disrupting Chemicals and Their Impacts in Patients with Renal DiseaseEnvironmental factors contribute to 22% of global mortality. In Taiwan, which has the highest prevalence of treated end-stage renal disease worldwide, approximately 10% of chronic kidney disease (CKD) cases remain of uncertain etiology. This highlights the urgent need to investigate environmental pollutants, particularly endocrine disrupting chemicals (EDCs), as potential nephrotoxins. Our study details findings from an integrated research project at Kaohsiung Chang Gung Memorial Hospital focusing on two emerging EDC classes in the CKD population: organophosphate flame retardants (OPFRs) and phthalates. Our research demonstrated a nearly 100% detection rate for OPFRs in the study population, indicating universal exposure. Cross-sectional analysis revealed that higher urinary OPFR levels were independently associated with lower eGFR and overt proteinuria, respectively. Notably, a two-year longitudinal study identified high OPFR exposure as a significant predictor for adverse renal events. Regarding phthalates, a one-year longitudinal study of patients with CKD uncovered the associations between phthalate exposure and increased renal injury biomarkers. Mediation analysis showed that exposure to phthalates might induce renal tubular injury through the mechanism of oxidative damage. In conclusion, these findings suggest that EDCs are pervasive environmental threats that might accelerate renal disease progression. Recognizing these hidden culprits is vital for developing preventive strategies and improving long-term outcomes for patients with renal disease.

• Key Highlights of the American Thyroid Association Thyroid and Pregnancy Guidelines
  Angela M. LeungUnited States Speaker Key Highlights of the American Thyroid Association Thyroid and Pregnancy GuidelinesThis session will present the key highlights of the American Thyroid Association 2026 guidelines for thyroid disease in preconception, pregnancy, and postpartum that have been published by a multidisciplinary group of experts with global perspective. The discussion will provide an overview of the methodology used to prepare these updated guidelines in partnership with and endorsed by several other collaborating societies. The presentation will cover the most notable changes and new recommendations surrounding thyroid function testing, iodine nutrition, infertility and assisted reproductive techniques, hypothyroidism, hyperthyroidism (including Graves’ disease), thyroid nodules, and thyroid cancers for women planning pregnancy, are pregnant, or seen for postpartum care.Thyroid Risks of Iodine ExcessIodine is a micronutrient that is required for the production of thyroid hormone. Iodine is commonly obtained from consuming an iodine-rich diet or iodine-fortified foods, amiodarone use, iodine-containing supplements, and iodinated contrast media. This session will review the potential forms of thyroid dysfunction arising from an acute iodine load, due to the failure to escape from the Wolff-Chaikoff effect and to the Jod-Basedow phenomenon. The risks of iodine excess in vulnerable populations, and current guidelines regarding the screening and monitoring of iodinated contrast-induced thyroid dysfunction, will be summarized.
• Precision Medicine in Gestational Thyroid Disease: Taking Care of Mother and Baby
  Marjorie A. RamosPhilippines Speaker Precision Medicine in Gestational Thyroid Disease: Taking Care of Mother and BabyPrecision medicine is revolutionizing the management of thyroid disorders in pregnancy by emphasizing individualized diagnosis, trimester-specific reference ranges, and tailored treatment strategies. Thyroid dysfunction is the second most common endocrine abnormality during gestation which poses significant risks to both maternal and fetal health, including miscarriage, preterm delivery, and impaired neurodevelopment. Guidelines now emphasize routine screening in high-risk populations, with tailored management protocols based on trimester-specific TSH and free T4 targets. For hypothyroidism, levothyroxine therapy is initiated early and titrated to maintain TSH in the lower half of the trimester-specific reference range, while hyperthyroidism is managed with antithyroid drugs at the lowest effective dose to minimize fetal risks. Recent updates to clinical guidelines highlight recommendations, including the importance of shared decision-making for women with Graves’ disease, and a shift from antibody-based to timing-based criteria for the treatment of subclinical hypothyroidism. These updates reflect evolving evidence from large randomized trials and systematic reviews, underscoring the need for flexibility and individualization in clinical practice. Future directions in precision medicine include the integration of genetic and molecular profiling to predict disease risk, response to therapy, and long-term outcomes. Machine learning and artificial intelligence are also being explored to enhance diagnostic accuracy and personalize prevention strategies for high-risk subgroups. By combining cutting-edge diagnostics with tailored therapeutic interventions, precision medicine aims to maximize maternal and fetal well-being, reduce adverse outcomes, and improve the overall quality of care for pregnant women with thyroid disorders. This presentation will review the latest evidence, guideline updates, and future innovations in precision medicine for gestational thyroid disease, providing clinicians with practical tools and insights for optimizing patient management in clinical practice and research settings
• Iodine Status in Pregnant Women in Taiwan
  Fan-Fen WangTaiwan Speaker Iodine Status in Pregnant Women in TaiwanIn the 1940’s, endemic goiter was the fifth most common disease in Taiwan. Then, in 1967, an island-wide salt-iodization campaign using 33 ppm potassium iodate was started. Four years after implementation of the campaign, goiter rates among schoolchildren had decreased from 21.6% to 4.3%, suggesting successful elimination of iodine deficiency. However, the mandatory salt iodization policy was discontinued in 2002. In recent surveys, the iodine nutrition status of the overall Taiwanese population has been found to be sufficient, but is at borderline level in pregnant women. Socioeconomic, environmental factors contribute to the incident iodine deficiency in subgroups. While about 92% of pregnant women in Taiwan take nutritional supplements, only about 49% take iodine-containing multi-vitamins. The iodine content of daily meals in Taiwan is currently under investigation, to support targeted dietary education and food fortification programs, which are indicated to improve the iodine status of pregnant women in Taiwan.